Status:
RECRUITING
Neoadjuvant Therapy in Cervical Cancer
Lead Sponsor:
Qilu Hospital of Shandong University
Collaborating Sponsors:
RemeGen Co., Ltd.
Conditions:
Uterine Cervical Neoplasms
Eligibility:
FEMALE
18-70 years
Phase:
NA
Brief Summary
In the comprehensive dataset of clinical diagnoses and treatments for cervical cancer in China, 49.8% of patients with stage IB3 and IIA2 receive surgical intervention following neoadjuvant chemothera...
Detailed Description
Primary research objectives: To evaluate the effect of Disitamab Vedotin combined with cisplatin on pathological response rate (pCR) of locally advanced cervical cancer. Secondary research objective...
Eligibility Criteria
Inclusion
- Clinical diagnosis of cervical squamous cell carcinoma
- HER-2 positive
Exclusion
- Cervical adenocarcinoma
Key Trial Info
Start Date :
October 20 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2026
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT06558682
Start Date
October 20 2024
End Date
October 1 2026
Last Update
April 1 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Qilu Hospital of Shandong University
Jinan, Shandong, China, 250012